GeneDx (WGS) Stock Price, News & Analysis

Company Overview

GeneDx Holdings Corp., doing business as GeneDx, is a genomic diagnostics company that provides genetic testing and interpretation services for patients with suspected rare and inherited conditions. The company combines sequencing technologies with clinical expertise and data analysis to help healthcare professionals identify genetic causes of disease and support diagnosis, treatment planning and patient management.

GeneDx’s offerings include whole exome and whole genome sequencing, as well as targeted testing for specific genetic disorders and hereditary cancer conditions. Its services are used by physicians, hospitals, health systems and other healthcare organizations, and the company also provides educational and interpretive resources intended to help clinicians understand genetic test results.

Founded in 2000, GeneDx was initially established to focus on genetic testing for rare diseases. The business was acquired by BioReference Laboratories in 2014 and later became part of Sema4, which acquired GeneDx from OPKO Health in 2022. Sema4 subsequently changed its corporate name to GeneDx Holdings Corp. and trades on the Nasdaq under the symbol WGS.

GeneDx primarily serves the U.S. healthcare market through healthcare providers and institutions, while its genomic testing and data capabilities support research and biopharmaceutical activities. The company is led by Chief Executive Officer Katherine Stueland.

Key Stats

• Today's Range: $58.06 to $58.06
• 50-Day Range: $56.15 to $104.95
• 52-Week Range: $32.21 to $170.87
• Volume: 12,201 shs
• Average Volume: 921,196 shs
• Market Capitalization: $1.87 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $90.86
• Consensus Rating: Moderate Buy

GeneDx Stock Analysis - MarketRank™

GeneDx scored higher than 67% of companies evaluated by MarketBeat, and ranked 240th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

GeneDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

GeneDx has a consensus price target of $90.86, representing about 61.8% upside from its current price of $56.15.

Amount of Analyst Coverage

GeneDx has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for GeneDx are expected to grow in the coming year, from ($0.41) to $1.15 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of GeneDx is -15.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of GeneDx is -15.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

GeneDx has a P/B Ratio of 5.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

25.21% of the float of GeneDx has been sold short.

Short Interest Ratio / Days to Cover

GeneDx has a short interest ratio ("days to cover") of 5.95.

Change versus previous month

Short interest in GeneDx has recently decreased by 4.39%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GeneDx does not currently pay a dividend.

Dividend Growth

GeneDx does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.46

News Sentiment

GeneDx has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for GeneDx this week, compared to 8 articles on an average week.

Search Interest

Only 3 people have searched for WGS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added GeneDx to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, GeneDx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,808,056.00 in company stock.

Percentage Held by Insiders

25.17% of the stock of GeneDx is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

61.72% of the stock of GeneDx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/03/2026
• Today: 10/26/2026
• Next Earnings (Confirmed): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: Healthcare Services
• Current Symbol: NASDAQ:WGS
• CIK: 1818331
• Web: www.genedx.com
• Phone: 800-298-6470
• Fax: N/A
• Employees: 1,300
• Year Founded: 2000

Price Target and Rating

• Average Price Target for GeneDx: $90.86
• High Price Target: $150.00
• Low Price Target: $63.00
• Potential Upside/Downside: +47.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.02 million
• Net Margins: -23.41%
• Pretax Margin: -23.39%
• Return on Equity: 4.12%
• Return on Assets: 2.26%

Debt

• Debt-to-Equity Ratio: 0.40
• Current Ratio: 3.30
• Quick Ratio: 3.06

Sales & Book Value

• Annual Sales: $427.54 million
• Price / Sales: 4.31
• Cash Flow: $2.52 per share
• Price / Cash Flow: 24.50
• Book Value: $10.54 per share
• Price / Book: 5.86

Miscellaneous

• Outstanding Shares: 29,820,000
• Free Float: 22,317,000
• Market Cap: $1.84 billion
• Optionable: Optionable
• Beta: 1.95